On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...

While Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent deadly ...

While Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil—a vaccine proven to prevent deadly cancers—reveals a troubling willingness to distort life-saving science for ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

Read about Merck, EssilorLuxottica, Wuxi Biologics and more in the latest Market Talks covering the Health Care sector.

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...